30 years of experience in the pharmaceutical industry, having worked in various management roles for several leading companies (Merck Generics, Mylan, Teva, etc).
From 2018 to October 2022, he held the role of Vice President and General Manager of Theramex.
His experience includes leading cross-functional teams, managing complex projects, successful launch of several cutting-edge products and implementing innovative business strategies delivering innovative solutions that meet patients and customer needs.
Has more than thirty years of experience in the pharmaceutical field, gained both in the context of multinationals such as Pfizer, Schering-Plough, Pharmacia, and in important CDMOs like Corden Pharma. He has covered the role of Chairman, CEO and board member in pharmaceutical companies in the last years. He holds a degree in Chemistry and Pharmaceutical Technologies obtained at the University of Milan.
He is a seasoned professional with significant experience in finance and operations management, particularly within the pharmaceutical industry. He is currently the Chief Financial Officer at SM Farmaceutici, where he manages corporate finance and supports strategic decision-making. Previously, he served as General Manager and Head of Production and Maintenance at Farmasol, a company specializing in dialysis concentrates, where he oversaw production, maintenance, and team coordination.
Has more than thirty years of experience in the pharmaceutical field, gained both in the context of multinationals such as Pfizer, Schering-Plough, Pharmacia, and in important CDMOs like Corden Pharma. He has covered the role of Chairman, CEO and board member in pharmaceutical companies in the last years. He holds a degree in Chemistry and Pharmaceutical Technologies obtained at the University of Milan.
Former medical oncologist with more than 25 years of experience in API branch of pharmaceutical industry: founder of Synbias Pharma Ltd. Main field of activity: management of new projects, API pharmaceutical facilities including fermentative processes, highly potent and highly toxic synthetic and semi-synthetic processes and final formulations pharmaceutical facilities including sterile filling of highly toxic compounds. Participation in GMP implementation at 3 manufacturing sites are also under his belt.
After the Bachelor’s degree in law at the “Università Statale” of Milan, she worked for around 20 years as a lawyer in leading Italian insurance companies, as head of Legal and Litigation departments.
In 2017 She founded a legal consultancy company, of which She is still the President, and in 2022 an innovative start-up operating in Human and Animal Healthcare.
Born in Parma - Graduated in economics and business, chartered accountant since 1976. He carried out his activity in corporate and fiscal matters always as an independent consultant, developing a whole range of knowledge in the field of tax and corporate matters, national and international. He worked in corporate restructuring operations such as mergers, demerger, liquidations, transfer of business and contribution in kind and completing several extraordinary operations of multinational companies belonging to the world's leading groups.
He worked with the Civil Court of Milan as technical advisor to the judge in numerous civil and tax litigations. In his more than fifty years of activity, he matured relations with prestigious in-ternational companies. He carried out and is currently still carrying out consulting activities in both cor-porate, banking, financial and insurance companies, taking care of the tax aspects of these companies, in terms of specific consultancy having the possibility to verify, study and solve delicate and complicated business situations, to implement commercial and financial contracts and to follow high-thickness tax litigation.
After graduating in Veterinary Medicine at the University of Milan, Enrico Pesenti spent three years as a researcher at the “Mario Negri Institute of Pharmacological Research” in Milan, Department of Immunology, and then started his career in the pharmaceutical industry, within Farmitalia-Carlo Erba, Pharmacia, Pfizer, and Nerviano Medical Sciences, acquiring a solid knowledge in cell biology, in vivo pharmacology and imaging, and a successful experience in anticancer therapies development.
In 2012 he was nominated Chief Executive Officer of Accelera Srl, a preclinical Contract Research Organization, part of the NMS Group, holding his position in the NMS Oncology organization as member of the Management Team. In 2021 he moved to Rottapharm Biotech as Director of Translational Pharmacology, with focus on innovative projects in Immuno-Oncology and Osteoarthritis. Since October 2022, Enrico is part of Crown Bioscience as Executive Director of Scientific Engagement. He is co-author of more than 50 peer-reviewed publications and co-inventor in several international patent applications.
A senior Quality Assurance and Quality Control professional with over 20 years of experience leading quality functions in the pharmaceutical and biotech industries. Throughout his career, he has overseen QA/QC management, risk assessments, and regulatory compliance for drug substance, drug product, and API manufacturing, ensuring adherence to cGMP standards and international regulations. As a Qualified Person (QP), he has managed batch release procedures and led quality teams across multiple sites, successfully navigating audits by global regulatory bodies such as the FDA and EMA.
His roles have included Senior Director of Global Quality at ADIENNE, Quality Unit Director at Nerpharma, and Site Quality Operations Leader at Zoetis, among others. He has extensive experience in managing quality systems, leading large teams, and implementing continuous improvement strategies, while ensuring product safety and compliance.He holds a degree in Chemical and Pharmaceutical Technologies and has completed specialized training in cGMP, FDA inspections, and pharmaceutical production. His expertise includes validation (IQ, OQ, PQ), risk management, and operational leadership in highly regulated environments.
We identified two platforms for development of innovative products, both covered by patents.
The first is based on the use of human ferritin nanoparticles associated with toxins, to target and eliminate cancer cells, minimizing damage to healthy tissues as much as possible. The same platform can be used for the delivery of oncological diagnostics but also drugs intended for other therapeutic areas.
The second platform uses new generation nanoparticles as a vehicle for both lipophilic and hydrophilic chemotherapics towards cancer cells. This new platform is the result of the most advanced research in the sector and will allow us to offer safer and more effective treatments to doctors and patients.
Our team is made up of professionals with decades of experience in formulation development, pre-clinical and clinical studies, registration, production, and marketing of drugs in compliance with the highest safety and quality standards.
